Loading...
Adjuvant endocrine therapy with tamoxifen or an aromatase inhibitor (AI) lengthens survival in postmenopausal women with receptor-positive early-stage breast cancer. In premenopausal women with such tumors, however, the role of postoperative adjuvant therapy (which also requires suppression of ovarian function with gonadotropin-releasing–hormone [GnRH] agonists) has been less clear. GnRH-agonist therapy is associated with rapid loss of BMD. In an industry-funded Austrian trial, investigators randomized 1803 premenopausal women with receptor-positive early-stage breast cancer to one of four adjuvant therapy regimens for 3 years. All participants received GnRH-agonist therapy. The four treatment arms were tamoxifen or the AI anastrozole, with…